Drug Design and Development

A Research Center More Than Twenty Years in the Making by Paul Erhardt
The notion of creating an academic-based drug design center within the University of Toledo's College of Pharmacy actually occurred a bit more than 20 years ago with the formation of what was initially called the "CDD." Such a conception at that time was truly unique and this should be attributed to the foresight of Drs. Wayne Hoss and Richard Hudson, both within the medicinal chemistry department wherein Richard was serving as Chair. It should be acknowledged that the CDD's first Director, Dr. Graham Durant, was a highly recognized scientist hired from industry where he and Dr. Robin Ganellin are credited with making the key medicinal chemistry contributions leading to the design and development of cimetidine, the firstin-class histamine H 2 antagonist [1]. Drawing upon start-up dollars and some lead-funding from Lilly, and working closely with faculty colleague Dr. Bill Messer, the early CDD was able to identify a selective muscarinic M 1 receptor agonist that was deemed meritorious for small molecule drug development as a potential treatment for Alzheimer's disease. However, Graham soon returned to industry and without his type of savvy residing within this academic setting, further drug development ceased and the CDD itself began to stagnate. I was hired from industry in the summer of 1994 as a tenured Professor with full academic responsibilities and by wearing a "second hat" to serve as the new Director for the CDD. The latter was in large part because I can be similarly cited for accomplishing the chemical design and development of a marketed drug, namely esmolol which is an ultra-short acting betaadrenergic receptor blocker that represents the firstin-class for a family of agents eventually to become known as "soft drugs" [2] .
From a Fading CDD to a Vibrant CD3
Left completely dependent upon extramural funding, the first few years were admittedly very humble for what I immediately renamed the "CD3" so as to emphasize the practical importance of "drug" "development" as well as "design." New to academe but not qualifying for young investigator awards, it wasn't until I joined a US National Institutes of Health, Small Business Innovation Research (NIH SBIR) Drug Development Study Section that I really learned how to write a quality grant application requisite for being a successful academic-based scientist. Eventually, the CD3's financial portfolio gradually grew to hover around USD 1 million per year and this continued for a run of several years. Extramural funding has been generated by public sector grants sprinkled with a healthy mix of private-sector sponsored research agreements (SRAs) and contracts. Total direct funding has surpassed well over USD 6 million and when the value of equipment obtained in the same manner is added, that number is close to USD 8.5 million. These dollars are primarily used to support a cadre of investigators and graduate students, at its peak including more than 25 interdisciplinary scientists who operated as a cohesive team to tackle cutting-edge research projects.
Mission and Technical Capabilities
The CD3 is a UT Board-approved core translational research center operating out of the College of Pharmacy and Pharmaceutical Sciences in close conjunction with the College of Medicine and Life Sciences. Its present mission has two aims. The first is to assist in the design and development of potential small molecule diagnostics/biomarkers, therapeutics or disease preventative agents with the goal of facilitating their translation into clinical applications. While focusing especially on technologies deriving from UT and Northern Ohio, the CD3 engages in collaborations or contracts that encompass the global health care research enterprise. The second but equally important aim of the CD3's mission stems from its base seated within an academic setting. Complimentary to the drug discovery initiatives, this involves the provision of unique opportunities for students to enhance their learning experiences by conducting both basic and applied research activities while participating as members of highly interdisciplinary teams. A variety of these experiences are offered to both young students and mature investigators ranging from high school via the CD3's "Shadow Program" all the way to sabbatical visitors, including in particular numerous opportunities for undergraduate, graduate, and postdoctoral students to become directly engaged in CD3 projects. In addition to being exposed to practical research problems, participation on the CD3's teams is itself a unique learning experience for many of these individuals.
The CD3 has assembled all of the requisite equipment and lab space along with a critical mass of interdisciplinary investigators. The CD3 scientists operate as a cohesive team so as to provide a high degree of expertise across seven core areas of competency relevant to drug design and development. These areas include: (i) computational chemistry and molecular modeling/docking studies; (ii) synthetic medicinal chemistry "hit-follow-up" and "early-ADMET-optimization" studies; (iii) frontline screening and biological testing using biochemical and cell culture assays in 96-well, semi-automated format; (iv) analytical and bioanalytical chemistry using "validated GLPcompliant" assay methods on LC-MS/MS instrumentation; (v) non-GMP scale-up and process chemistry optimization; (vi) secondary pharmacological and advanced ADMET-PK studies in vitro and in vivo; and (vii) intellectual property and patent protection strategies. Specializing in the development of small molecule agents showing promise for diagnostic/biomarker, treatment or disease prevention paradigms, the CD3 can thus assist in the translation of molecular biology and clinical concepts all the way to a US Investigational New Drug (IND) application required to establish their safety and ultimately validate their utility in the clinic.
In addition to providing this critical core of expertise and technical capabilities, the CD3 personnel continue to enthusiastically engage in a number of educational initiatives. For example, in addition to my own faculty-mandated efforts, two of the CD3's senior research staff, Drs. Jeff Sarver and Jill Trendel (molecular biology/cell-based testing) are voluntary members of UT's Graduate School so that they can be officially recognized participants on MS and PhD thesis committees. Dr. Trendel also participates in a number of activities intended to tweak younger students' interests in science such as career fairs including conducting a mock crime scene that allows for hands-on forensic chemistry experience.
As part of CD3's community outreach, a "Team CD3" regularly gears up for the annual Susan G. Komen "Race for the Cure" breast cancer fundraiser held in Toledo. In 2012, thanks largely to the Team CD3 co-captains Rachael Jetson (PhD 2013) and her daughter Autumn, our "family" of runners and walkers ultimately went-on to win two types of team participation awards [3] .
Drug Design and Development
Accomplishments and a Glimpse at Today's Projects
With continued respect for our CDD predecessors, the aforementioned muscarinic technology was eventually developed to the point of an IND submission, in the end by having the new CD3 assist a spin-off company formed by Drs. Hoss and Messer so as to garner Small Business Innovation Research (SBIR) funding while also tapping the development resources provided by the NIH National Institute of Mental Health (NIMH). That technology has subsequently been licensed by a small biotech company and they are moving it through clinical testing. Likewise, new soft drug technologies developed by the CD3 were licensed to a different small biotech company, and just recently another spinoff company has been formed to advance a technology for manipulating stem cells to provide a specific type of bone therapy. One of the CD3's most interdisciplinary projects has involved three-way collaboration with the US Department of Agriculture (USDA) and Tulane University to pursue unique natural products derived from stressed soybeans. These compounds have potential anticancer effects as well as other therapeutic possibilities [4] . Promising advanced stage projects today include three UT technologies and one from a small company contractor that are nearing the point where we will be selecting a compound for each to be moved into preclinical development. Equally important but at the front end of the overall drug discovery-development spectrum, the CD3 has assisted in preparing stronger grant proposals submitted by numerous UT Principal Investigators seeking to uncover new biological pathways or natural products amenable to being exploited for potential therapies.
In terms of numbers, across the last 20 years the CD3 has worked with UT to submit 18 patent applications, published 48 scientific papers, and contributed 24 books, chapters, or reviews that discuss technical details and strategies of medicinal chemistry and the process of small molecule drug discovery. And on the educational front, more than 15 postdocs, visiting scientists, and sabbatical research investigators encompassing 5 other Nations have trained within the CD3; 8 PhD and 12 Master students have undertaken CD3 projects, graduated and gone on to successful careers in both academia and industry while another 4 will matriculate during the next year; well over 100 Master and PhD students have had one or more CD3 personnel on their thesis research committees; more than 50 undergraduate students have utilized the CD3 to enrich their overall academic experience by taking advantage of our practical lab research activities either for course credit or on their own volition so as to assist in assessing their personal career path options; and finally, more than a dozen high school and undecided undergraduate majors have taken advantage of the CD3's "Shadow Program" to observe what real, non-textbook laboratory research is like. The CD3 has received several awards for its Graduate Level Teaching, its Professional Level Teaching (for both pharmacy graduate and undergraduate students), and from a regional high school for our "Shadow Program." 
A Research Center More Than Twenty Years in the Making
CD3's Exemplary Relationship to Medicinal Chemistry within an Evolving Pharmaceutical Enterprise
Two themes have heavily influenced the evolution of today's practice of health care research within the US, one deriving from the public sector and the other from the private sector. The first largely reflects the directions that the NIH has emphasized over the last 25 years. Beginning with its commitment to delineate the human genome, this was followed by the pursuit of proteomics to discern the genome's function at the molecular biology level, and then by the establishment of high-throughput screening (HTS) centers to identify small molecule ligands that can associate with a given protein of interest. The latter, in turn, prompted the assembly of small molecule compound libraries that can be requested from the NIH by academicians for use in biological tests that represent the first step toward the identification of eventual diagnostic or therapeutic interventions for humans. As a result, "millions of people are [now] looking to science to deliver new and better ways to detect, treat and prevent disease" [5] . Responding to this expectation, the NIH has more recently launched the National Center for Advancing Translational Sciences (NCATS) which intends to take advantage of our expanding knowledge in a manner that parallels the path previously utilized exclusively by the private sector to discover new pharmaceutical products [6, 7] . In line with words used to describe the CD3's operations, "from the outset, [the NCATS] will encourage everyone to break the invisible barriers of program boxes and to think as one cohesive team" [8] . Underscoring two aspects of this first theme that are relevant to the CD3's exemplary nature: (i) The NIH has made "substantial investments in the past decade to provide academic institutions with the capabilities for early-stage drug discovery, such as HTS of large compound libraries and medicinal chemistry for hit optimization" [9] ; and, (ii) With a USD 576 million start-up package [7] and the mission of the still-evolving NCATS now being elaborated, it is becoming very clear that the NIH emphasis to encourage drug discovery and development within academe will not only continue, but is likely to grow to an even larger extent in the future. The other theme that has contributed significantly toward shaping health care research derives from the corporate side of the global pharmaceutical enterprise. Over the last 10 years, several factors have combined to cause fewer new chemical entities (NCEs) to be launched into the marketplace. Even worse, this decline has been accompanied by soaring costs to conduct pharmaceutical research and development (R&D) coupled to a consumer audience that will no longer tolerate a paralleled increase in product pricing to maintain profit margins. One recent estimate concludes "that the number of new US FDA-approved drugs per billion dollars of R&D spending has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms [10] . That fewer new drugs have been launched [10] [11] [12] [13] stems, in part, from the industry's struggle to sort through the flood of new technologies that can now be considered during drug discovery. For example, while the "marriage of HTS to combinatorial chemistry" and the latter's compound libraries [14, 15] was embraced by many companies so as to expedite the early phases of drug discovery by identifying initial "hit compounds" much faster, this practice has also made the overall process considerably less efficient in terms of a broader knowledgegain and, in the end, has had little positive impact upon the actual quality of "drug wannabe" [16] compounds entering preclinical/clinical testing. Disappointingly, the attrition rate still runs at almost 90% for late-stage drug candidates failing to achieve market launch [10] [11] [12] [13] [14] [15] [16] . Attempts to address attrition during clinical testing have focused heavily upon improving candidate compounds' drug-likenesses compared to successfully marketed agents. This is being pursued by conducting early-stage screening that intends to predict overall clinical performance relative to a given agent's absorption, distribution, metabolism, excretion, and toxicity, the so-called ADMET profile that becomes so very critical upon administration of drugs to humans. Unlike efficacy, however, the success of ADMET screens to predict such behavior in humans remains very much in its infancy and relying upon them in a similar high-throughput fashion to simply remove potentially problematic drugs from the pipeline early-on can be premature and can again become counter-productive in terms of generating specific structure-activity relationship (SAR) knowledge about how to deal with these types of shortcomings in general so as to eventually enhance the overall process. Thus, while attrition due to poor ADMET features is purportedly less, it is simply because fewer compounds are allowed through this earlier funneling process, with the down-side again being that little knowledge is being created to actually address such matters for efficaciously meritorious candidates. This overall situation becomes exacerbated in that endstage attrition purportedly now remains high because compounds do not perform as efficaciously as hoped Drug Design and Development in the clinic. Interestingly, the basic research needed to close the ADMET assessment gap in a knowledgeable manner and to break the catch-22 loop just mentioned above, may actually be better performed within an academic setting seeking to uncover fundamental principles rather than trying to focus upon the fastest possible generation of a new drug per se [14] [15] [16] . And, in turn, perhaps an academic-based drug discovery center is thus ideally poised to pursue both types of activities in a synergistic manner.
The aforementioned soaring R&D costs and the consumers' intolerance for price increases associated with pharmaceutical products clearly reflect the overall economic environment. The former is also coupled to an escalation of safety testing that has been gradually imposed by the US Federal Drug Administration (FDA) [10] , while the latter is additionally coupled with the growing latitude afforded to US health care insurance companies to decide what they will and will not pay. Both of these bureaucratic influences further serve to make the overall process of drug discovery that much more difficult for "big pharma" to undertake alone. Considering all of the above factors, the present course of action being pursued by many of the larger players within the pharmaceutical industry is to decrease their efforts directed toward the early stages of drug discovery while placing more emphasis upon later development and clinical testing stages. Their source for new technologies to develop, in turn, draws from the nearly 20-year proliferation of small entrepreneurial shops, and from the more recent trend in academic labs that have become engaged in basic and applied drug-related research activities. According to some, "after several years of cutting back on R&D, the industry [has become] desperate for innovation and is willing to pay a premium for promising compounds" [17] . Thus, three aspects of this second theme can be underscored as being pertinent to the CD3's exemplary nature: (i) in perfect alignment with the public sector's emphasis, the private sector is likewise looking more and more toward academic labs as a source for new drug molecules; (ii) in this case, however, technology transfer becomes a pivotal connecting feature wherein it should be additionally emphasized that the more successful academic partners will be those that can groom their discovered technologies to points that are highly conducive for all parties to be able to repeatedly negotiate the most mutually beneficial transfer agreements, e.g. while that most often being ideal when technologies have been advanced all the way to a successful Phase I Clinical study accompanied by a biomarker for efficacy, this can vary for every given case; and finally, (iii) there appear to be several points during grooming technologies across early-stage discovery to mid-stage development wherein hurdles, such as those associated with predicting ADMET behavior in the clinic, may be better addressed within an academic setting having a cadre of interdisciplinary expertise that can work together as a cohesive team to merge basic and applied research in the most seamless manner possible.
Responding to the public and private sector themes described above, a flurry of so-called drug discovery initiatives have been started within academic settings. A recent survey indicates "seventy-eight units in the U.S. were identified as small-molecule drug discovery centers situated within universities or nonprofit research organizations" [9] . 20 years ago that number certainly would have been less than 10, probably less than 5. Thus, as a final and rather distinct point of pride for UT and its College of Pharmacy and Pharmaceutical Sciences, the CD3 is not only one of the numbers cited in the recent survey, but it also would have been one of the few "way ahead of its time" units already in operation more than 20 years ago. In line with this most recent trend while appreciative of our long-standing history, the CD3 has itself joined the still maturing "Academic Drug Discovery Consortium" that intends to "bring-together the growing number of university-led drug discovery centers and programs" [18] .
It is clear that this is a very exciting time for medicinal chemistry. The CD3 is pleased that its longstanding emphasis upon contributing fundamental chemical knowledge in the form of SAR data as part of interdisciplinary research teams, is now becoming restored as a critical component residing at the forefront of new drug discovery. In this regard I look forward to sharing in a future issue of CI some of the insights I have gained while serving as the CD3's director that may be useful to today's academic-based drug discovery centers.
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